Batch Details: IP5-A2
Ipamorelin is a research-grade growth hormone secretagogue (GHS) that directly targets the ghrelin receptor on pituitary somatotrophs to induce GH release. Its high selectivity profile allows investigators to probe GH/IGF-1 signaling, tissue remodeling, and metabolic outcomes while minimizing confounding from off-target adrenal activation seen in older GH-releasing compounds.
Research Significance
Potent stimulator of pulsatile GH secretion via GHS-R1a activation
High selectivity with comparatively low activity on ACTH/cortisol, enabling cleaner interpretation of somatotropic effects
Supports investigation of GH–IGF-1 axis in muscle protein synthesis, repair, and recovery
Useful in combination studies with GHRH analogues (e.g. CJC-1295 w/o DAC, Sermorelin) to evaluate synergistic GH release
Potential Research Applications
Endocrine mapping of GH/IGF-1 signaling cascades and feedback regulation
Muscle regeneration, soft-tissue repair, and recovery models
Body composition studies focusing on lean mass accrual and adipose modulation
Metabolic research on glucose and lipid utilization downstream of GH pulses
Specifications
Form: Lyophilized peptide powder
Content: Ipamorelin 5 mg per vial
Identity: Synthetic pentapeptide, selective ghrelin receptor (GHS-R1a) agonist
Storage: Store at −20 °C; once reconstituted, use promptly under sterile lab conditions
